The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Diagnosis of diabetes mellitus type 1 or type 2 with
Glycosylated hemoglobin A1c (HbA1c) less than or equal to (≤) 9% and
Presence of bilateral pain in lower extremities due to DPN (defined as a symmetric, length-dependent sensory or sensorimotor polyneuropathy) for at least 1 year
Painful neuropathy other than DPN
History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months